Compare Abrdn Physical Platinum Shares ETF (PPLT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs TG Therapeutics Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $15.25 (market cap $1.93B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 4.2× Abrdn Physical Platinum Shares ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 42 Days and TG Therapeutics Inc for 16 Days on average.
| PPLT | TGTX | |
|---|---|---|
Market Cap | $1.93B | $8.16B |
Volume | 1,698,523 | 1,735,121 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $59.06 |
52-Week Low | $13.73 | $26.94 |
Typical Hold Time | 42 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT (abrdn Physical Platinum Shares ETF) trades at $14.82, up 0.27% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF faces headwinds from platinum's term structure in contango, indicating adequate supply. Recent news highlights platinum's underperformance relative to other precious metals, though some analysts see potential for catch-up trading given the valuation gap.
The outlook remains cautious with technical indicators favoring short positions, while fundamental supply dynamics and historical seasonality present conflicting signals. Key risks include commodity price volatility and industrial demand fluctuations, though institutional interest may provide support if platinum regains momentum in the precious metals complex.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
